"It's too early to reach firm conclusions about the full extent of the overall survival benefit of adding bevacizumab Avastin to the treatment regimen for newly diagnosed ovarian cancer, but it does seem very promising, particularly for patients at high risk of recurrence," said Dr. Gunnar Kristensen an investigator in the study from the Norwegian Radium Hospital in Oslo, Norway. At a previous medical meeting, researchers reported that treatment with Avastin and chemotherapy extended the time before tumors progressed compared to chemotherapy alone -- achieving the study's primary endpoint. Genentech intends to seek approval for Avastin in ovarian cancer later this year, pending discussions with the U.S. Food and Drug Administration over how much survival data will be necessary before the drug can be reviewed and potentially approved, said Genentech spokesperson Krysta Pellegrino. Several other companies are presenting data on ovarian cancer drugs at this year's ASCO meeting, including Exelixis ( EXEL), Nektar Therapeutics ( NKTR) and Endocyte ( ECYT). --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.